ASAntonia Morita Iswari Saktiawati

Antonia Morita Iswari Saktiawati

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Antonia Morita Iswari Saktiawati has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Integrating machine learning and artificial intelligence in the management of Acinetobacter infections: a narrative review

    by Brice Boris Legba, Sinikiwe Dube, Tomislav Meštrović, Khandmaa Dashnyam, Antonia Morita Iswari Saktiawati, Francesco Maurelli, Ryota Matsuyama, Victorien Dougnon, Shymaa Enany

    Acinetobacter baumannii, particularly in its multidrug-resistant (MDR) and carbapenem-resistant (CRAB) forms, has become a major global health concern due to its ability to survive in hospital environments, acquire resistance rapidly, and cause severe infections with high mortality. Conventional diagnostic and therapeutic strategies remain slow, imprecise, and difficult to implement, especially in resource-limited settings, highlighting the need for innovative approaches. Advances in artificial intelligence (AI) and machine learning (ML) offer powerful tools to strengthen every stage of Acinetobacter infection management. This narrative review synthesizes current evidence on how AI enhances early detection, improves species-level identification, predicts antimicrobial resistance from genomic data, accelerates drug discovery, and supports real-time hospital surveillance and outbreak control. AI-driven methods enable faster triage, more accurate differentiation between colonization and true infection, robust prediction of resistance phenotypes, and efficient identification of synergistic antibiotic combinations. Moreover, AI-supported drug discovery pipelines have recently yielded novel agents such as abaucin, demonstrating the potential of computational approaches to explore new chemical spaces. Despite these promising advances, challenges persist regarding data quality, generalizability across settings, interpretability, and ethical considerations including privacy and algorithmic bias. Successful integration of AI into clinical practice will require rigorous model validation, equitable data governance, and strong collaboration between clinicians, microbiologists, and data scientists. Overall, AI represents a transformative opportunity to reduce the clinical and economic burden of Acinetobacter infections and to strengthen global antimicrobial resistance surveillance.

  • Implementation Fidelity of Diabetes Mellitus Screening Among Tuberculosis Patients in Primary Healthcare in Karanganyar District, Indonesia: A Mixed‐Method Study

    by Clarissa Augustania, Antonia Morita Iswari Saktiawati, Ari Probandari

    Background: Indonesia faces a dual burden of high tuberculosis (TB) burden and rising diabetes mellitus (DM) prevalence. Given that DM is a significant risk factor for TB, screening people with TB for DM comorbidity is important for early management to mitigate adverse outcomes. Objectives: This study aimed to measure the degree of implementation fidelity, moderating factors, and barriers to implementing DM screening among TB patients in Indonesia's Primary Healthcare setting. Methods: A sequential explanatory mixed method was used. A cross‐sectional survey was conducted with 42 Directly Observed Treatment, Short‐course providers to assess adherence to DM screening guidelines. Screening coverage was evaluated through the TB information system. In‐depth interviews with providers, managers, and patients identified key barriers and enablers. Results: Screening coverage ranges from 36.3% to 97.6% between 2020 and 2024. High fidelity was reported among providers, with 95% screening for DM at the time of TB diagnosis. Facilitators included TB‐DM policy availability, screening affordability, provision of equipment, and patients' responsiveness. However, delays in data reporting and insufficient cross‐sector collaboration posed challenges to the implementation. Conclusion: Despite positive progress in integrating TB‐DM care, addressing barriers is essential to optimize the programme's impact. Strengthening reporting mechanisms and fostering collaboration could enhance programme outcomes.


  • Tuberculosis in Indonesia: challenges and future directions

    by Antonia Morita Iswari Saktiawati, Ari Probandari


  • Open Access

    Strategies to Enhance Diagnostic Capabilities for the New Drug-Resistant Tuberculosis (DR-TB) Drugs

    by Antonia Morita Iswari Saktiawati, Anca Vasiliu, Francesca Saluzzo, Onno W. Akkerman

    The global burden of drug-resistant tuberculosis (DR-TB) continues to challenge healthcare systems worldwide. There is a critical need to tackle DR-TB by enhancing diagnostics and drug susceptibility testing (DST) capabilities, particularly for emerging DR-TB drugs. This endeavor is crucial to optimize the efficacy of new therapeutic regimens and prevent the resistance and overuse of these invaluable weapons. Despite this urgency, there remains a lack of comprehensive review of public health measures aimed at improving the diagnostics and DST capabilities. In this review, we outline strategies to enhance the capabilities, especially tailored to address the challenges posed by resistance to new DR-TB drugs. We discuss the current landscape of DR-TB drugs, existing diagnostic and susceptibility testing methods, and notable gaps and challenges in these methods and explore strategies for ensuring fair access to DST while narrowing these disparities. The strategies include public health interventions aimed at strengthening laboratory infrastructure, workforce training, and quality assurance programs, technology transfer initiatives, involving drug developers in the DST development, establishing national or regional referral hubs, fostering collaboration and resources pooling with other infection control efforts, extending testing access in underserved areas through public–private partnerships, advocating for lowering costs or loans at low interest, remote technical support, and implementing mandatory molecular surveillance monitoring. This review underscores the urgent need to enhance DST capacities for new DR-TB drugs and identifies opportunities for innovation and improvement. Assessing the extent of the global health impact of these measures is crucial to ensure their effectiveness in combating DR-TB.


  • Open Access

    Strategies to Enhance Diagnostic Capabilities for the New Drug-Resistant Tuberculosis (DR-TB) Drugs

    by Antonia Morita Iswari Saktiawati, Anca Vasiliu, Francesca Saluzzo, Onno Akkerman

    The global burden of drug-resistant tuberculosis (DR-TB) continues to challenge healthcare systems worldwide. There is a critical need to tackle DR-TB by enhancing diagnostics and drug susceptibility testing (DST) capabilities, particularly for emerging DR-TB drugs. This endeavor is crucial to optimize the efficacy of new therapeutic regimens and prevent the resistance and overuse of these invaluable weapons. Despite this urgency, there remains a lack of comprehensive review on public health measures aimed at improving the diagnostics and DST capabilities. In this review, we outline strategies to enhance the capabilities especially tailored to address the challenges posed by resistance to new DR-TB drugs. We discuss the current landscape of DR-TB drugs, existing diagnostic and susceptibility testing methods, notable gaps and challenges in these methods, and explore strategies for ensuring fair access to DST while narrowing these disparities. The strategies include public health interventions aimed at strengthening laboratory infrastructure, workforce training, and quality assurance programs, technology transfer initiatives, involving drug developers in the DST development, establishing national or regional referral hubs, fostering collaboration and resources pooling with other infection control efforts, extending testing access in underserved areas through public-private partnerships, advocating for lowering costs or loans at low-interest, remote technical support, and implementing mandatory molecular surveillance monitoring. This review underscores the urgent need to enhance DST capacities for new DR-TB drugs and identifies opportunities for innovation and improvement. Assessing the extent of the global health impact of these measures is crucial to ensure their effectiveness in combating DR-TB.


  • The potential of an electronic nose as a screening tool for tuberculosis (TB)

    by Antonia Saktiawati, Kuwat Triyana, Shidiq Hidayat, Riris Ahmad, Ari Probandari, Dian Nurputra, Yodi Mahendradhata

    Background: TB remains a global health threat, particularly in resource-limited regions where early diagnosis is challenging. There is a pressing need for an accurate, affordable, and non-invasive diagnostic tool. Breath analysis, which detects specific volatile organic compounds, holds promise for disease detection. We developed an electronic nose (e-Nose) inspired by human olfaction, augmented with artificial intelligence, to screen for TB through breath samples. Method: Conducted in diverse Indonesian cities (Yogyakarta, Klaten, Surakarta, and Papua), our study trained the e-Nose to distinguish individuals with TB from healthy subjects and those with other respiratory conditions. Afterward, we tested the e-Nose on presumptive TB patients. Participants provided breath samples into air-collecting bags, which were analyzed by the e-Nose connected to a laptop. Support Vector Machine algorithms processed the data. Diagnostic accuracy was assessed against composite reference standards, integrating clinical symptoms, bacteriological examination, chest X-ray, and follow-up. Ethical clearance was obtained, and participants provided informed consent. Result: We trained the e-Nose to 27 individuals with TB, 24 healthy controls, and 53 with other respiratory diseases (median age: 43 years; BMI: 19.5 kg/m²). We tested it on 1383 people screened for TB. No adverse events occurred. In the training phase, the e-Nose had a sensitivity of 95% (95% CI=77-100%) and specificity of 82% (95% CI=60-95%). Analysis of the testing phase is ongoing. Conclusion: In this development phase, the e-Nose had high sensitivity and specificity. Further research is imperative to validate its performance across larger and diverse populations.

  • Open Access

    Landscape of TB Infection and Prevention among People Living with HIV

    by Anca Vasiliu, Rebecca Abelman, Yousra Kherabi, Antonia Morita Iswari Saktiawati, Alexander Kay

    Tuberculosis (TB) is one of the leading causes of mortality in people living with HIV (PLHIV) and contributes to up to a third of deaths in this population. The World Health Organization guidelines aim to target early detection and treatment of TB among PLHIV, particularly in high-prevalence and low-resource settings. Prevention plays a key role in the fight against TB among PLHIV. This review explores TB screening tools available for PLHIV, including symptom-based screening, chest radiography, tuberculin skin tests, interferon gamma release assays, and serum biomarkers. We then review TB Preventive Treatment (TPT), shown to reduce the progression to active TB and mortality among PLHIV, and available TPT regimens. Last, we highlight policy-practice gaps and barriers to implementation as well as ongoing research needs to lower the burden of TB and HIV coinfection through preventive activities, innovative diagnostic tests, and cost-effectiveness studies.


  • Open Access

    Implementing molecular tuberculosis diagnostic methods in limited-resource and high-burden countries

    by Anca Vasiliu, Antonia Morita Iswari Saktiawati, Raquel Duarte, Christoph Lange, Daniela Maria Cirillo

    Tuberculosis (TB) is one of the deadliest infectious diseases in the world with more than a million people dying of TB each year. Accurate and timely TB diagnosis has the potential to alleviate the global TB burden; therefore, one of the pillars of the End TB Strategy developed by the World Health Organization (WHO) is the early diagnosis of TB, including universal drug-susceptibility testing (DST). The WHO emphasises the importance of DST before treatment initiation, using molecular WHO-recommended rapid diagnostic tests (mWRDs). Currently available mWRDs are nucleic acid amplification tests, line probe assays, whole genome sequencing, and targeted next-generation sequencing. However, implementing the sequencing mWRDs in routine laboratories in low-income countries is constrained by the existing infrastructure, high cost, the specialised skills needed, data storage, and the current delay in results compared with other routine methods. These limitations are pronounced in resource-limited settings, which often have a high TB burden and need for innovative TB diagnostic technologies. In this article we propose several possible solutions, like adapting infrastructure capacity to needs, advocating for lowering costs, building bioinformatics and laboratory capacity, and increasing the use of open-access resources for software and publications.


  • Open Access

    Sosialisasi Pencegahan Penyakit TBC untuk Masyarakat

    by Sulistyani Prabu Aji, Antonia Morita Iswari Saktiawati

    Sosialisasi ini bertujuan: untuk menaruh pengenalan & penyuluhan pencegahan penyakit TBC untuk menaikkan pencerahan warga mengenai bahaya penyakit TBC & pencegahannya. Metode aktivitas yg dipakai pada darma ini pada bentuk pembinaan/workshop dan output pembinaan diperesentasikan masing-masing kelompok, melalui beberapa tahapan yaitu: 1) ceramah 2) simulasi 3) eksplorasi 4) pembimbingan & 5) evaluasi. Khalayak target atau peserta penyuluhan merupakan warga Kota Palangkaraya. Hasil menurut aktivitas darma mengambarkan bahwa warga sangat antusias mengikuti aktivitas penyuluhan terlihat menggunakan adanya respon yang sangat baik. Mengingat aktivitas ini sangat krusial buat menambah pengetahuan warga maka aktivitas ini bisa pada lanjutkan pada lingkungan warga bawah lainnya supaya bisa menjaga kebersihan


  • Open Access

    eNose-TB: A trial study protocol of electronic nose for tuberculosis screening in Indonesia

    by Antonia Morita Iswari Saktiawati, Kuwat Triyana, Siska Dian Wahyuningtias, Bintari Dwihardiani, Trisna Julian, Shidiq Nur Hidayat, Riris Andono Ahmad, Ari Probandari, Yodi Mahendradhata

    Background: Even though conceptually, Tuberculosis (TB) is almost always curable, it is currently the world’s leading infectious killer. Patients with pulmonary TB are the source of transmission. Approximately 23% of the world’s population is believed to be latently infected with TB bacteria, and 5–15% of them will progress at any point in time to develop the disease. There was a global diagnostic gap of 2.9 million between notifications of new cases and the estimated number of incident cases, and Indonesia carries the third-highest of this gap. Therefore, screening TB among the community is of great importance to prevent further transmission and infection. The electronic nose for screening TB (eNose-TB) project is initiated in Yogyakarta, Indonesia, to screen TB by breath test with an electronic-nose that is easy-to-use, point-of-care, does not expose patients to radiation, and can be produced at low cost. Methods/Design: The objectives of the two-phase planned project are to: 1) investigate the potential of an eNose-TB as a screening tool in Indonesia, in comparison with screening with clinical symptoms and chest radiology, which are currently used as a standard, and 2) analyze the time and cost of a screening algorithm with eNose-TB to obtain additional case detection. A cross-sectional study will be conducted in the first phase to validate the eNose-TB. The validation phase will involve 395 presumptive TB patients in the Surakarta General Hospital, Central Java. In the second phase, a cross-sectional research will be conducted, involving 1,383 adults and children in the municipality of Yogyakarta and Kulon Progo district of Yogyakarta Province. Discussion: The findings will provide data concerning the sensitivity and specificity of the eNose-TB as a screening tool for tuberculosis, and the time and cost analysis of a screening algorithm with the eNose. Trial registration: NCT04567498; https://clinicaltrials.gov/.